2021 年第 12 期 第 16 卷

复方骨肽注射液与盐酸氨基葡萄糖联合治疗膝骨关节炎的临床效果和安全性及对患者炎性因子水平和免疫功能的影响

Clinical efficacy and safety of compound ossotide injection combined with glucosamine hydrochloride on the treatment of patients with knee osteoarthritis and its effects on inflammatory factor levels and immune function

作者：刘建玉李岩高杰

英文作者：Liu Jianyu Li Yan Gao Jie

单位：山东省第二人民医院骨科中心，济南250000

英文单位：Orthopaedic Center Shandong Second Provincial General Hospital Jinan 250000 China

关键词：膝骨关节炎；复方骨肽注射液；盐酸氨基葡萄糖

英文关键词：Kneeosteoarthritis;Compoundossotideinjection;Glucosaminehydrochloride

• 摘要：

• 目的 分析复方骨肽注射液联合盐酸氨基葡萄糖治疗膝骨关节炎（KOA）的临床效果和安全性及对患者炎性因子水平和免疫功能的影响。方法 选取2018年3月至2020年3月山东省第二人民医院收治的124例KOA患者作为研究对象。根据随机数字表法将其分为观察组与对照组，各62例。对照组采用依托考昔治疗，观察组采用复方骨肽注射液联合盐酸氨基葡萄糖治疗，均治疗1个月。通过比较2组的各项临床指标，评价不同治疗方法的临床效果和安全性及对KOA患者炎性因子水平及免疫功能的影响。结果  观察组总有效率高于对照组［93.5%（58/62）比80.6%（50/62）］，差异有统计学意义（P＜0.05）。治疗后2组白细胞介素1β、白细胞介素18、肿瘤坏死因子α水平及美国西部安大略大学和麦克马斯特大学骨关节炎指数评分均低于治疗前，且观察组均低于对照组（均P<0.05）。治疗后2组CD+4、CD+4/CD+8比值均显著高于治疗前，且观察组均高于对照组，而CD+8显著低于治疗前，且观察组低于对照组（均P＜0.05）。观察组并发症总发生率及随访3、12个月膝关节疼痛复发率均低于对照组［3.2%（2/62）比12.9%（8/62）、4.8%（3/62）比17.7%（11/62）、8.1%（5/62）比22.6%（14/62）］（均P＜0.05）。结论  复方骨肽注射液联合盐酸氨基葡萄糖能有效降低KOA患者的炎性因子水平，提高免疫功能，疗效显著且安全性较高。

• Objective To analyze the clinical efficacy and safety of compound ossotide injection combined with glucosamine hydrochloride on the treatment of paitents with knee osteoarthritis (KOA) and its effects on inflammatory factors level and immune function. Methods From March 2018 to March 2020, 124 patients with KOA admitted to Shandong Second Provincial General Hospital were selected. They were randomly divided into observation group and control group, with 62 cases in each group. The control group was treated with etoricoxib, and the observation group was treated with compound ossotide injection combined with glucosamine hydrochloride, both for 1 month. The different treatments on the clinical efficacy and safety, immune function and inflammatory factors of patients with KOA were evaluated by comparing each clinical indicator between the two groups. Results The total effective rate of the observation group was higher than that of the control group［93.5%(58/62) vs 80.6%(50/62)］(P<0.05). After treatment, the levels of interleukin-1β, interleukin-18, tumor necrosis factor-α and Western Ontario and McMaster Universities Osteoarthritis Index score of both groups were lower than those before treatment, and those of the observation group were lower than those of the control group(all P<0.05). After treatment, the levels of CD+4, CD+4/CD+8 ratio of both groups were significantly higher than those before treatment, and those of the observation group were higher than those of the control group, while CD+8 of both groups was significantly lower than that before treatment, and that of the observation group was lower than that of the control group(all P<0.05). The total incidence of complications and the recurrence rate of knee joint pain followed-up for 3 and 12 months of the observation group were lower than those of the control group ［3.2%（2/62） vs 12.9%（8/62）, 4.8%（3/62） vs 17.7%（11/62）, 8.1%（5/62） vs 22.6%（14/62）］(all P<0.05). Conclusion  The combination of compound ossotide injection and glucosamine hydrochloride can effectively reduce the levels of inflammatory factors and improve immune function in patients with KOA, with significant efficacy and high safety.